Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
125 people get PRX articles and Market Currents by email alert.
Get email alerts on PRX »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
PR Newswire (Sep 28, 2012)
-
3 Drugmakers Trading Near Highs With Strong Receivable TrendsKapitall • Thu, Aug 16, 2012 -
PR Newswire (Aug 2, 2012)
-
-
-
PR Newswire (Jul 16, 2012)
-
PR Newswire (Jul 13, 2012)
-
-
PR Newswire (Jul 9, 2012)
-
-
7 Rallying Healthcare Stocks Undervalued By EPS TrendsKapitall • Wed, May 9, 2012
-
PR Newswire (May 8, 2012)
-
Stifel Nicolaus Sees An Opportunity In Horizon Pharma SharesBen Yoffe • Tue, May 8, 2012
-
-
PR Newswire (Apr 19, 2012)
-
Valeant: Ready To Move On Increased R&DStock Croc • Thu, Apr 12, 2012 -
-
PR Newswire (Apr 9, 2012)
To learn more about Seeking Alpha Pro, click here.
-
3 Drugmakers Trading Near Highs With Strong Receivable TrendsKapitall • Thu, Aug 16, 2012
-
-
-
-
7 Rallying Healthcare Stocks Undervalued By EPS TrendsKapitall • Wed, May 9, 2012
-
Stifel Nicolaus Sees An Opportunity In Horizon Pharma SharesBen Yoffe • Tue, May 8, 2012
-
-
Valeant: Ready To Move On Increased R&DStock Croc • Thu, Apr 12, 2012
-
-
Winning Long-Term Plays In Generic DrugsValueMax • Thu, Apr 5, 2012
-
-
-
-
-
Upside Winners Abbott, Johnson & Johnson Each Worth Over $80Takeover Analyst • Thu, Jan 5, 2012 -
-
Greenblatt's Magic Formula Portfolio Quarterly UpdateValue Research • Wed, Nov 30, 2011
-
-
Emisphere: Crown Jewel In Oral B12Josh Franklin • Fri, Oct 7, 2011 -
-
Par Pharmaceutical Companies Inc Q4 2008 Earnings Call TranscriptTue, Mar 3, 2009
-
Par Pharmaceutical Companies Inc. Q3 2008 Earnings Call TranscriptFri, Nov 7, 2008
-
Par Pharmaceutical Companies, Inc. Q2 2008 Earnings Call TranscriptFri, Aug 8, 2008
-
Par Pharmaceutical Companies Inc. Q1 2008 Earnings Call TranscriptMon, Jun 2, 2008
-
Par Pharmaceutical Companies Inc. Q1 2008 Earnings Call TranscriptFri, May 30, 2008
-
Par Pharmaceuticals Inc Q4 2007 Earnings Call TranscriptMon, Mar 24, 2008
-
PR Newswire (Sep 28, 2012)
-
PR Newswire (Aug 2, 2012)
-
at CNBC.com (Jul 16, 2012)
-
at MarketWatch.com (Jul 16, 2012)
-
at CNBC.com (Jul 16, 2012)
-
at CNBC.com (Jul 16, 2012)
-
at CNBC.com (Jul 16, 2012)
-
PR Newswire (Jul 16, 2012)
-
PR Newswire (Jul 13, 2012)
-
PR Newswire (Jul 9, 2012)
-
PR Newswire (May 8, 2012)
-
PR Newswire (Apr 19, 2012)
-
PR Newswire (Apr 9, 2012)
-
PR Newswire (Apr 6, 2012)
-
at MarketWatch.com (Feb 28, 2012)
-
PR Newswire (Dec 5, 2011)
-
at MarketWatch.com (Feb 24, 2011)
-
at MarketWatch.com (Dec 7, 2010)
-
at MarketWatch.com (Aug 2, 2010)
PRX vs. ETF Alternatives
Company Description
Par Pharmaceutical Companies, Inc., incorporated in 1978 as Par Pharmaceutical, Inc., is a Delaware holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc., is in the business of developing, licensing, manufacturing and distributing generic and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, January 2, 12:24 PM Par Pharmaceutical (PRX +0.2%) says that its operating subsidiary has begun shipping 5 mg and 10 mg strengths of rizatriptan benzoate tablets. Rizatriptan benzoate is indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years of age. Annual U.S. sales of the drug total approximately $653M. 1 Comment [Healthcare]
- Wednesday, December 26, 2012, 5:00 PM Depomed (DEPO) says that its lawsuits against two filers of Abbreviated New Drug Applications for Gralise have been dismissed at its own request. The dismissal was requested after Watson Laboratories (WPI) withdrew its application, and Par Pharmaceutical (PRX) amended its to no longer seek approval prior to the expiration of DEPO's Gralise patents listed for in the FDA's Orange Book. Comment! [Healthcare]
- Friday, December 14, 2012, 1:43 PM AstraZeneca (AZN +0.2%) says an Appeals Court has upheld the decision finding that the substance patent protecting Crestor is valid and enforceable. The defendants may seek a rehearing or review by the U.S. Supreme Court. Absent a reversal, none of the Abbreviated New Drug Applications filed may be approved by the FDA prior to expiration of the patent, which expires in 2016. The ruling covers rosuvastatin calcium, the active ingredient in Crestor. Comment! [Healthcare]
- Tuesday, October 16, 2012, 8:14 AM Watson Pharmaceuticals (WPI) expects to close its $5.9B acquisition of Swiss peer Actavis by early November after it yesterday received FTC permission for the deal, adding to EU authorization earlier this month. Under the conditions of the approval, Watson must sell 14 generic drugs to Par Pharmaceuticals (PRX) and four to Sandoz. (PR) Comment! [Healthcare]
- Friday, September 28, 2012, 11:47 AM A U.S. appeals court upholds a lower court ruling in favor of Pozen (POZN -0.8%) against Par Pharmaceutical (PRX), Alphapharm and Dr. Reddy’s Laboratories (RDY +1.9%), affirming the district court's earlier decision that found POZN's patent valid, and blocked PRX and RDY from selling a generic version of POZN's migraine drug Treximet until 2025. Comment! [Healthcare]
- Wednesday, September 12, 2012, 4:04 PM Stifel Nicolaus ups its target from $8 to $11 on Santarus (SNTS +5%) on the back of its highly successful Phase 3 results for Rifamycin SV MMX in traveler’s diarrhea, and it's successful appeal against Par Pharmaceuticals (PRX). The firm thinks that Zegerid will gain an extra $35M-$45M in annual sales as a result of the court decision, and it maintains a Buy rating on the stock. Comment! [Healthcare, On the Move]
- Thursday, August 2, 2012, 10:32 AM Par Pharmaceutical (PRX): Q2 EPS of $1.62 beats by $0.52. Revenue of $294.3M (+36.9% Y/Y) beats by $3.M. (PR) Comment! [Earnings, Healthcare]
- Thursday, August 2, 2012, 12:05 AM Notable earnings before Thursday’s open: AEE, APA, ARIA, BDX, CAH, CI, CNP, DNR, DTV, DUK, ENB, GM, INCY, K, MFA, NNN, OCN, PGN, PH, PRX, PWR, PXP, RDC, SBH, SE, SEE, SHO, SNE, SRE, TDC, TE, TEVA, TIE, TWC, UPL, VIAB, VRX, WNR, XEL Comment! [Earnings]
- Wednesday, August 1, 2012, 5:30 PM Notable earnings before Thursday’s open: AEE, APA, ARIA, BDX, CAH, CI, CNP, DNR, DTV, DUK, ENB, GM, INCY, K, MFA, NNN, OCN, PGN, PH, PRX, PWR, PXP, RDC, SBH, SE, SEE, SHO, SNE, SRE, TDC, TE, TEVA, TIE, TWC, UPL, VIAB, VRX, WNR, XEL Comment! [Earnings]
- Tuesday, July 17, 2012, 4:30 PM Somaxon Pharmaceuticals (SOMX) settles its patent litigation suit with Mylan (MYL) and Par Pharmaceutical (PRX) involving Silenor 3 mg and 6 mg tablets. The settlement grants MYL the exclusive right to begin selling a generic version of Silenor on January 1, 2020, and PRX the right to begin selling a generic version 180 days after a third party generic version is first sold in the U.S. under a license from Somaxon. Comment! [Healthcare]
-
Monday, July 16, 2012, 9:10 AM
Premarket gainers: PRX +39%. CONM +13%. AUTH +13%. SVU +6%.
Losers: ISR -19%. NSPH -6%. ANR -6%. Comment! [On the Move] - Monday, July 16, 2012, 8:24 AM TPG agrees to acquire Par Pharmaceutical (PRX) for $1.9B, or $50/share, which represents a 37% premium over Par's closing price on Friday. Shares +36% premarket. (PR) Comment! [Healthcare, Breaking News, On the Move, M&A]
- Tuesday, July 3, 2012, 11:24 AM The FTC has approved an amended final order settling charges that Teva's (TEVA +1.3%) proposed acquisition of Cephalon would have been anti-competitive for several generic drugs. The order requires Teva to sell the rights and assets related to a generic cancer pain drug and a generic muscle relaxant to Par Pharmaceuticals (PRX -0.6%), and allow PRX to sell a generic version of Cephalon's narcolepsy drug Provigil in 2012. Comment! [Healthcare, Global & FX]
- Wednesday, May 30, 2012, 12:48 PM Goldman says the court ruling against Par Pharmaceutical (PRX -1.3%) regarding patents covering Lovaza eliminates a key upside opportunity, adding that the extent of the impact on growth is unclear at this point. The firm maintains its Neutral rating on the shares. Comment! [Healthcare]
- Wednesday, May 30, 2012, 12:26 PM Shares of Amarin (AMRN -3.5%) give back much of yesterday's pop on news that Teva Pharmaceutical (TEVA) and Par Pharmaceutical (PRX) lost their bid to sell the generic form of Lovaza. The stock had rocketed higher on perceptions that the court ruling would clear the way for Amarin's AMR101 to launch and price without competition from generic Lovaza products. 2 Comments [Healthcare, On the Move]
- Tuesday, May 29, 2012, 6:44 PM A Delaware court has upheld two patents in favor of Pronova's heart drug Lovaza, ruling against Par Pharmaceutical (PRX) and Teva Pharmaceutical (TEVA). The ruling prevents Par and Teva from selling generic versions of Lovaza, which lowers very high levels of triglycerides in the bloodstream. 4 Comments [Healthcare]
-
Asif Suria
Par Pharmaceutical Companies Enters Into Definitive Agreement To Be Acquired By TPG for $50.00 per share in cash $PRX http://bit.ly/MzNM8g - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
MagicDiligence
Par Pharma - Buried in the Generic Drugs Battlefield $PRX $TEVA $ACT $MYL $NVS http://stk.ly/kB9i9C - View all 0 replies
-
MagicDiligence
Weekly roundup of stocks moving in and out of Magic Formula Investing $MANT $VRX $PRX others http://stk.ly/eQAh4P - View all 0 replies
-
MagicDiligence
Stocks moving in and out of Joel Greenblatt's Magic Formula Investing screens this week $MRVL $ADI $PRX others http://stk.ly/fTvWeZ - View all 0 replies
-
MagicDiligence
Par Pharmaceuticals $PRX new to MFI. Generic drugs will be huge over next 2 years. Great balance sheet too. - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES